{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:13:04Z","timestamp":1780668784115,"version":"3.54.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arcmed.2026.103387","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:40:35Z","timestamp":1769769635000},"page":"103387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence"],"prefix":"10.1016","volume":"57","author":[{"given":"Mariana M.","family":"Ram\u00edrez-Mej\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3259-4291","authenticated-orcid":false,"given":"Guadalupe","family":"Ponciano-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Poo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-8048","authenticated-orcid":false,"given":"Nahum","family":"M\u00e9ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.arcmed.2026.103387_bib0001","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.arcmed.2026.103387_bib0003","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arcmed.2026.103387_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s44355-024-00017-5","article-title":"Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation\/accessibility of Resmetirom","volume":"2","author":"Brennan","year":"2025","journal-title":"npj Gut and Liver"},{"key":"10.1016\/j.arcmed.2026.103387_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70242-8","article-title":"Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-\u03b2 agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"14","author":"Suvarna","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2026.103387_bib0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5604\/16652681.1226814","article-title":"Management strategies for liver fibrosis","volume":"16","author":"Altamirano-Barrera","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0007","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.arcmed.2026.103387_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101421","article-title":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Schwabe","year":"2025","journal-title":"JHEP Reports"},{"key":"10.1016\/j.arcmed.2026.103387_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1411279","article-title":"Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review","volume":"11","author":"Han","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.arcmed.2026.103387_bib0010","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1002\/iid3.1335","article-title":"Pirfenidone use in fibrotic diseases: What do we know so far?","volume":"12","author":"Torre","year":"2024","journal-title":"Immunity, Inflammation and Disease"},{"key":"10.1016\/j.arcmed.2026.103387_bib0011","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.15420\/cfr.2021.30","article-title":"Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond","volume":"8","author":"Aimo","year":"2022","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.arcmed.2026.103387_bib0012","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.dld.2004.05.012","article-title":"The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen \u03b11(I), TIMP-1 and MMP-2","volume":"36","author":"Di Sario","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.arcmed.2026.103387_bib0013","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","article-title":"Pirfenidone effectively reverses experimental liver fibrosis","volume":"37","author":"Garc\u00eda","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/srep44754","article-title":"Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis","volume":"7","author":"Komiya","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2026.103387_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23251","article-title":"Pirfenidone attenuates nonalcoholic fatty liver disease through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway","volume":"37","author":"Xie","year":"2023","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.751499","article-title":"Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiac in-vitro and in-vivo models","volume":"9","author":"Sartiani","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.arcmed.2026.103387_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70131","article-title":"Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial","volume":"45","author":"Mu\u00f1oz-Espinosa","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.arcmed.2026.103387_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101472","article-title":"Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023","volume":"29","author":"Munoz-Espinosa","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13148-025-01969-y","article-title":"HCV patients with residual fibrosis after DAA treatment re-establish their epigenetic signature after prolonged-release pirfenidone: MINERVA study","volume":"17","author":"Cerda-Reyes","year":"2025","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.arcmed.2026.103387_bib0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12072-020-10069-3","article-title":"Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study","volume":"14","author":"Poo","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.arcmed.2026.103387_bib0021","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0022","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0023","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/ijms19072034","article-title":"New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis","volume":"19","author":"Mendez-Sanchez","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2026.103387_bib0024","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"issue":"25","key":"10.1016\/j.arcmed.2026.103387_bib0025","article-title":"Mechanisms and therapeutic insights into MASH-associated fibrosis","volume":"S1043\u20132760","author":"Zhu","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2026.103387_bib0026","article-title":"Heterogeneity and Function of Kupffer Cells in Liver Injury","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0027","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41423-025-01313-7","article-title":"Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells","volume":"22","author":"Kostallari","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0028","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13578-024-01267-9","article-title":"New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease","volume":"14","author":"Zhang","year":"2024","journal-title":"Cell Biosci"},{"key":"10.1016\/j.arcmed.2026.103387_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110357","article-title":"Macrophage in liver Fibrosis: Identities and mechanisms","volume":"120","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1494250","article-title":"The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0032","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2026.103387_bib0033","article-title":"Signaling pathways that activate hepatic stellate cells during liver fibrosis","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.arcmed.2026.103387_bib0034","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41419-021-04377-1","article-title":"Initiation of hepatic stellate cell activation extends into chronic liver disease","volume":"12","author":"De Smet","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.arcmed.2026.103387_bib0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0036","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00535-008-2180-y","article-title":"Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies","volume":"43","author":"Li","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0037","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.3892\/mmr.2017.7641","article-title":"PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review)","volume":"16","author":"Ying","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.arcmed.2026.103387_bib0038","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.apsb.2022.01.007","article-title":"Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases","volume":"12","author":"Fu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.arcmed.2026.103387_bib0039","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3390\/antiox12091653","article-title":"Oxidative Stress in Liver Pathophysiology and Disease","volume":"12","author":"Allameh","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.arcmed.2026.103387_bib0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/livers2040023","article-title":"Role of Oxidative Stress in Liver Disorders","volume":"2","author":"Conde de la Rosa","year":"2022","journal-title":"Livers"},{"key":"10.1016\/j.arcmed.2026.103387_bib0041","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ijms25010410","article-title":"Redox Biology and Liver Fibrosis","volume":"25","author":"Bellanti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2026.103387_bib0042","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ceca.2014.07.008","article-title":"Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus","volume":"56","author":"Avila","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.arcmed.2026.103387_bib0043","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1755-1536-3-16","article-title":"The multifaceted role of pirfenidone and its novel targets","volume":"3","author":"Mac\u00edas-Barrag\u00e1n","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.arcmed.2026.103387_bib0044","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/dna.2024.0194","article-title":"Pirfenidone Downregulates eIF6, P311, and TGF-\u03b2 Expression and Improves Liver Fibrosis Induced by Bile Duct Ligation in Wistar Rats: Evidence for Liver Regeneration","volume":"44","author":"Yousefi","year":"2025","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.14218\/JCTH.2025.00029","article-title":"Exploring the Therapeutic Potential of TGF-\u03b2 Inhibitors for Liver Fibrosis: Targeting Multiple Signaling Pathways","volume":"13","author":"Zhu","year":"2025","journal-title":"J clin transl hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0046","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arcmed.2026.103387_bib0047","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-230X-14-131","article-title":"Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C","volume":"14","author":"Flores-Contreras","year":"2014","journal-title":"BMC Gastroenterology"},{"key":"10.1016\/j.arcmed.2026.103387_bib0048","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/toxsci\/kfu184","article-title":"Activation of the Nrf2-ARE pathway in hepatocytes protects against steatosis in nutritionally induced non-alcoholic steatohepatitis in mice","volume":"142","author":"Lee","year":"2014","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.arcmed.2026.103387_bib0049","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2004.07.007","article-title":"Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes","volume":"41","author":"Nakanishi","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2011.12.025","article-title":"Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis","volume":"678","author":"Navarro-Partida","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0051","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41374-019-0255-4","article-title":"Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages","volume":"99","author":"Chen","year":"2019","journal-title":"Lab Invest"},{"key":"10.1016\/j.arcmed.2026.103387_bib0052","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/17501911.2025.2579498","article-title":"The epigenetic roles of pirfenidone - implication in liver disease management","volume":"17","author":"Rosas-Campos","year":"2025","journal-title":"Epigenomics"},{"key":"10.1016\/j.arcmed.2026.103387_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75458-2","article-title":"H3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH","volume":"14","author":"Rodriguez-Sanabria","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2026.103387_bib0054","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1136\/gut.2006.107136","article-title":"A pilot study in patients with established advanced liver fibrosis using pirfenidone","volume":"55","author":"Armend\u00e1riz-Borunda","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.arcmed.2026.103387_bib0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jceh.2019.12.005","article-title":"Repurposing Pirfenidone for Nonalcoholic Steatohepatitis-related Cirrhosis: A Case Series","volume":"8","author":"Philips","year":"2020","journal-title":"J clin transl hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0056","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/ph18091321","article-title":"Present and Future Perspectives in the Treatment of Liver Fibrosis","volume":"18","author":"Cerrito","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.arcmed.2026.103387_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.874408","article-title":"New Drugs for Hepatic Fibrosis","volume":"13","author":"Shan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/jpps.2023.11808","article-title":"Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches","volume":"26","author":"Mohammed","year":"2023","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.arcmed.2026.103387_bib0059","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2026.103387_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70920","article-title":"Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"8","author":"Shakeel","year":"2025","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.arcmed.2026.103387_bib0061","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2026.103387_bib0062","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2026.103387_bib0063","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2026.103387_bib0064","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.arcmed.2026.103387_bib0065","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arcmed.2026.103387_bib0066","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4254\/wjh.v15.i2.201","article-title":"Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis","volume":"15","author":"Kram","year":"2023","journal-title":"World J Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0067","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2026.103387_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.102112","article-title":"Implications of liver fibrosis in clinical trials","volume":"30","author":"Jahagirdar","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0069","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S2468-1253(16)30110-8","article-title":"Antifibrotics in chronic liver disease: tractable targets and translational challenges","volume":"1","author":"Ramachandran","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2026.103387_bib0070","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844092600010X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844092600010X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:22:27Z","timestamp":1780665747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018844092600010X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S018844092600010X"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2026.103387","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2026.103387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103387"}}